Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or ...

While DCTs failed to transform clinical research, artificial intelligence (AI)-powered study approaches are now fulfilling their promise within the non-interventional research space. Unified, digital ...

In the Phase III ENVISION trial, Zusduri achieved a 24-month duration of response rate of 72.2% among patients with a ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, shares key ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how digital twins provide patient-level predictions that ...

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

In the Phase III TRIUMpH program, tegoprazan met primary endpoints and outperformed lansoprazole in maintaining healing of ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, outlines the key ...